Journals / Astım Allerji İmmünoloji / 2015 / Cilt: 13 - Sayı: 3

Treatment modalities for primary immunodefi ciencies

Primer immünyetmezliklerde tedavi yöntemleri Primer immünyetmezliklerde tedavi yöntemleri

Pages
103–115
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, treatment modalities of PIDs were aimed to be reviewed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Primary immunodefi ciencies (PIDs) are inherited disorders in which one or several components of immune system are aff ected.
📊
Key Findings & Data:PIDs comprises more than 200 diff erent disorders and the number of newly recognized defi ciencies is still increasing.
💡
Conclusion & Impact:In this review, treatment modalities of PIDs were aimed to be reviewed
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Primary immunodefi ciencies (PIDs) are inherited disorders in which one or several components of immune system are aff ected. PIDs comprises more than 200 diff erent disorders and the number of newly recognized defi ciencies is still increasing. PIDs are characterized by an increased susceptibility to infections, allergy, autoimmune disorders, autoinfl ammation, lymphoproliferation, hemophagocytosis, and malignancies. Infectious diseases are a major source of morbiditiy and mortality in the majority of patients with PIDs. Th erefore, prevention and treatment of infectious disease are important as curative treatment. Basis for the treatment of PIDs include; reduce exposure to infectious agents, antimicrobial prophylaxis, vaccine applications, aggressive treatment of infections, regulation of the immune system with various agents (eg. immunoglobulin), and reconstitution of the immune system with hematopoietic stem cell transplantation or gene therapy. In this review, treatment modalities of PIDs were aimed to be reviewed

Özet

Primer immünyetmezlikler (PİY) immün sistemin bir veya bir kaç bileşeninin etkilendiği kalıtımsal hastalıklardır. PİY'ler 200'den fazla hastalıktan oluşur ve yeni tanımlanan bozukluklarla bu sayı artmaktadır. PİY'ler infeksiyonlara karşı artmış duyarlılık, allerji, otoimmün hastalıklar, otoinfl amasyon, lenfoproliferasyon, hemofagositoz ve malinitelerle karakterizedir. İnfeksiyon hastalıkları PİY'li hastaların çoğunluğunda morbidite ve mortalitenin önemli nedenini oluşturur. Bundan dolayı, infeksiyon hastalıklarının önlenmesi ve tedavisi küratif tedaviler kadar önemlidir. PİY'lerde tedavinin temelini; infeksiyöz ajanlara maruziyetin azaltılması, antimikrobiyal profilaksi, aşı uygulamaları, infeksiyonların agresif tedavisi, çeşitli ajanlarla immünitenin düzenlenmesi (immünglobulin gibi) ve hematopoetik kök hücre nakli veya gen tedavisi ile immün sistemin yeniden yapılandırılması oluşturur. Bu derlemede, PİY'lerin tedavi yöntemlerinin gözden geçirilmesi amaçlanmıştır

🔖

Cite This Article

AYTEKİN, C. (2015). Treatment modalities for primary immunodefi ciencies. Astım Allerji İmmünoloji, Cilt: 13 - Sayı: 3, 103–115. https://ajindex.com/articles/150449

References (9)

  1. Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr 2014;2:77. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol 2013;33:1-7.
  2. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162. Sanal O, Tezcan I. Th irty years of primary immunodeficiencies in Turkey. Ann N Y Acad Sci 2011;1238:15-23.
  3. Kilic SS, Ozel M, Hafizoglu D, Karaca NE, Aksu G, Kutukculer N. Th e prevalences [correction] and patient characteristics of primary immunodeficiency diseases in Turkey-two centers study. J Clin Immunol 2013;33:74-83.
  4. Basturk B, Sari S, Aral A, Dalgic B. Prevalence of selective immunoglobulin a deficiency in healthy Turkish school children. Turk J Pediatr 2011;53:364-8.
  5. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014;312:729-38.
  6. Yorulmaz A, Artaç H, Kara R, Keleş S, Reisli İ. Primer immün yetmezlikli 1054 olgunun retrospektif değerlendirilmesi. Astım Allerji İmmünoloji 2008;6:127-34.
  7. Stiehm ER, Chapel HM. Conventional therapy of primary immunodeficiency diseases. In: Ochs HD, Smith CIE, Puck JM (eds). Primary immunodeficiency diseases: A molecular and genetic approach. 3rd ed. New York: Oxford University Press, 2013:833-53.
  8. Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in 2013. J Allergy Clin Immunol 2014;133:967-76. van Zelm MC, van der Burg M, Langerak AW, van Dongen JJ. PID comes full circle: applications of V(D)J recombination excision circles in research, diagnostics and newborn screening of primary immunodeficiency disorders. Front Immunol 2011;2:12. Yarmohammadi H, Cunningham-Rundles C. Treatment of primary immunodeficiency diseases. In: Rezaei N, Aghamohammadi A, Notarangelo LD (eds). Primary immunodeficiency diseases: Definition, diagnosis, and management. Berlin-Heidelberg: Springer, 2008:315-34.
  9. Pachlopnik Schmid J, Güngör T, Seger R. Modern management of primary T-cell immunodeficiencies. Pediatr Allergy Immunol Papadopoulou-Alataki E, Hassan A, Davies EG. Pr